TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04848467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine (CVnCoV)
Description: Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine (CVnCoV)
Description: Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Description: One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Description: One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One intramuscular injection as normal saline \[0.9% NaCl\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One intramuscular injection as normal saline \[0.9% NaCl\].
Study: NCT05523752

Intervention type: DEVICE
Group type: OTHER
Intervention: Proseal Laryngeal Mask
Description: insertion of Proseal Laryngeal Mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Classic Laryngeal Mask
Description: insertion of Classic Laryngeal Mask

Intervention type: DEVICE
Group type: OTHER
Intervention: I-gel
Description: insertion of I-gel

Intervention type: DEVICE
Group type: OTHER
Intervention: Suprema Laryngeal Mask
Description: insertion of Suprema Laryngeal Mask
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product B with 1.5% nicotine
Description: P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05366816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
Study: NCT04786821

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Exercise Training
Description: Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoenix Exoskeleton suit
Description: Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
Study: NCT06422221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
Study: NCT05859152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zona Pellucida-Bound Sperm Selection for ICSI
Description: one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Embryologist Selected Sperm
Description: one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
Study: NCT05232279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testofen 300mg
Description: Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testofen 600mg
Description: Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
Study: NCT05798546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-T
Description: Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
Study: NCT06020313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol Experimental
Description: The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol Experimental
Description: The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06014203

Intervention type: DIAGNOSTIC_TEST
Intervention: Edema measurement
Description: Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel
Study: NCT05424796

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Physiological saline
Description: Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hemostasis and cavity disinfection with NaOCl
Description: Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
Study: NCT05014789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-IQ technology 2.0
Description: All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
Study: NCT05798546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
Study: NCT05625295

Intervention type: OTHER
Intervention: data collection protocol in clinical history
Description: collection of data from the clinical history according to the established protocol

Intervention type: OTHER
Intervention: data collection protocol in clinical history
Description: collection of data from the clinical history according to the established protocol
Study: NCT06228482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05829005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
Study: NCT06200168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz.
Study: NCT06491940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Patients will receives Losartan (LS) 50 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan + Hydrochlorothiazide
Description: Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
Study: NCT06200168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antiemetic treatment
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation.
Study: NCT04447300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high power application
Description: Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
Study: NCT06200168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard antiemetic treatment
Description: Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
Study: NCT04892524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual multidisciplinary review
Description: The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
Study: NCT06511479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND-BP
Description: 8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOOST
Description: The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
Study: NCT05143905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7503
Description: Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive placebo by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive placebo by SC injection
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product C with 1.5% nicotine
Description: P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT05143905

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive placebo by SC injection
Study: NCT05924581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment of spinal stiffness
Description: The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions.
Study: NCT04447300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard power application
Description: Standard power application
Study: NCT06254092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tourniquet binding of cervical
Description: The procedure will be performed by surgeons with rich experience in clinical work
Study: NCT05373095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PKC (adapted adherence counseling) and Conditional Cash Transfers
Description: The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
Study: NCT05088330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: treatment with D-VRD in NDMM
Study: NCT05351177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
Study: NCT05606848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Emulsion (TPF-T)
Description: All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foods for special medical purposes [FSMP] for patients with tumors
Description: All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy.
Study: NCT05239884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study: NCT06176781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol Sequential Therapy
Description: Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).